Amyloid and lipids in the pathology of Alzheimer disease
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
In the last decade, we have witnessed an avalanche of information about the morphological and biochemical changes that occur in Alzheimer disease (AD). This knowledge has provided new strategies for treatment and identified possible approaches for prevention. Because AD pathology is relentlessly progressive, occurring over years or decades, successful treatment will depend on early intervention and therefore recognition of risk factors that lead to the development of this dementia. In the present review, we advance some of the alterations of lipid and membrane metabolism, alone or in association with β-amyloid peptide (AP), as pivotal components of AD pathophysiology. At present, the 40 and 42 amino acid long Aβ, resulting from the intracellular proteolytic processing of the β-amyloid precursor protein (AβPP), have deservedly taken center stage in investigations throughout the world. Fibrillar Aβ42 and Aβ40 are preferentially deposited in neuritic plaques1 and in vascular walls2, respectively. In a very limited number of families, genetic mutations invariably lead to AD dementia. The discovery of over 40 different mutations in the genescoding for AβPP and presenilins 1 and 2 provides clear evidence of multiple etiologies for familial AD3,4. However, in sporadic AD, which represents over 95% of the patients with this dementia, the underlying genetic, physiological and environmental factors leading to Aβ deposition remain elusive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Self-citationApolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Cited by
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783
Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., & Martins, R. N. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001854 · Cited by 388
Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer’s Disease
Roher, A. E., Esh, C., Kokjohn, T. A., Kalback, W., Luehrs, D. C., Seward, J. D., Sue, L. I., & Beach, T. G. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000095973.42032.44 · Cited by 280
Self-citationMild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology
Pappolla, M. A., Bryant-Thomas, T. K., Herbert, D., Pacheco, J., Fabra Garcia, M., Manjon, M., Girones, X., Henry, T. L., Matsubara, E., Zambon, D., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000070182.02537.84 · Cited by 247
Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease
Poirier, J. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00007-8 · Cited by 116
Metadata
- Authors
- Roher, A. E., Kuo, Y.-M., Kokjohn, K. M., Emmerling, M. R., & Gracon, S.
- Venue
- Amyloid
- Publisher
- Informa UK Limited
- Published
- 1999-01
- Volume
- 6
- Issue
- 2
- Pages
- 136-145
- ISSN
- 1350-6129 (ISSN-L)
- 1744-2818
- OpenAlex
- W2050920707
- Cited by
- 63
- References
- 24
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid and lipids in the pathology of Alzheimer disease. https://app.cochat.ai/papers/10.3109/13506129909007315
- The paper
- Roher, A. E., Kuo, Y.-M., Kokjohn, K. M., Emmerling, M. R., & Gracon, S. (1999). Amyloid and lipids in the pathology of Alzheimer disease. Amyloid. https://doi.org/10.3109/13506129909007315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.